FDA approves Roche's giredestrant pill for ESR1-mutated breast cancer
The FDA approved Wilserdly with everolimus for advanced ESR1-mutated breast cancer after a trial showed slower progression; survival data are not yet mature.
Read MoreViews: (76)
Our creativity scripted in words.
Tags: Giredestrant
The FDA approved Wilserdly with everolimus for advanced ESR1-mutated breast cancer after a trial showed slower progression; survival data are not yet mature.